IDH1 and chondrosarcoma: This is in line with our previous results in which we also did not find any correlation between IDH1 or -2 mutation status in sensitivity for inhibitors of glutaminolysis [34], NAD synthesis [35] or Bcl-2 family members in chondrosarcoma cells, while in other tumor types there was a clear difference in sensitivity [36–38].